Rimonabant - Wikipedia

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn ...

Acomplia: Uses, Dosage, Side Effects & Warnings - Drugs.com

Sanofi-Aventis has withdrawn rimonabant from the market globally and it is no longer under development. 1 Acomplia was officially withdrawn by the European Medicines ...

Rimonabant - an overview | ScienceDirect Topics

Atrial fibrillation has been attributed to rimonabant in two cases [114 A]. • A man who took rimonabant for 5 weeks developed palpitation, fatigue, and exertional ...

Rimonabant | C22H21Cl3N4O - PubChem - The PubChem Project

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1.

Rimonabant – Wikipedia

Rimonabant ist ein Arzneistoff, der als Appetitzügler zur Behandlung des Übergewichts eingesetzt wurde, eigentlich allerdings zur Raucherentwöhnung von dem ...

Acomplia (Rimonabant) – Investigational Agent for the ...

Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works...Read More...

Rimonabanto – Wikipédia, a enciclopédia livre

Rimonabant ou rimonabanto é um fármaco que era utilizado para redução do peso e afinamento da cintura. Em Abril de 2006 o laboratório Sanofi-Aventis anunciou a ...

リモナバン - Wikipedia

リモナバン（リモナバント, 英語: Rimonabant, SR141716）は、選択的な カンナビノイド受容体タイプ1 （英語版） の拮抗薬で ...

Rimonabant - Wikipedia

Il Rimonabant (o SR141716) è un farmaco antiobesità anoressizzante, ritirato dal mercato. Si tratta di un agonista inverso per il recettore CB1 dei cannabinoidi.

Rimonabant — Wikipédia

Le rimonabant (ou SR141716) est un médicament anorexigène contre l'obésité agissant comme un agoniste inverse des récepteurs cannabinoïdes CB1.